BALVERSA 5mg (Erdafitinib Tablet) 5 mg

BALVERSA 5mg (erdafitinib) tablets are prescribed for treating specific types of bladder cancer. This medication is designed to target cancer cells and is available in a 28-tablet pack. Store below 25°C and consult a healthcare provider for suitability.

Strength

5 mg

Pack Size

28s

Storage

Below 25°C

Manufacturer / TM Owner

Janssen Products

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BALVERSA 5mg (erdafitinib) is used to treat adults with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. It is typically prescribed when cancer has progressed despite prior platinum-based chemotherapy. This medication works by targeting specific genetic changes in cancer cells. It is not a first-line treatment and should be used under medical supervision.

Side Effects

BALVERSA 5mg (erdafitinib) may cause side effects such as mouth sores, fatigue, or changes in vision. Some users report digestive discomfort like nausea or diarrhea. Skin reactions, including dryness or rash, are also possible. These effects vary in intensity and should be monitored by a healthcare professional.

Precautions & Warnings

Keep BALVERSA 5mg (erdafitinib) tablets in their original packaging and store below 25°C. Avoid exposure to moisture or direct sunlight. Do not crush, split, or chew the tablets. Inform your doctor about any pre-existing eye conditions or skin disorders before starting this medication.

Avoid Interactions

BALVERSA 5mg (erdafitinib) may interact with certain medications, including strong CYP3A4 inhibitors or inducers, which can affect its effectiveness. Avoid grapefruit products while taking this drug. Discuss all current medications, including over-the-counter and herbal supplements, with your healthcare provider to minimize risks.

Frequently Asked Questions

BALVERSA 5mg (erdafitinib) is used to treat adults with advanced or metastatic bladder cancer that has progressed after platinum-based chemotherapy.

Store BALVERSA 5mg tablets below 25°C in their original packaging, away from moisture and direct sunlight.

Common side effects include mouth sores, fatigue, vision changes, nausea, diarrhea, and skin reactions like dryness or rash.

Consult your doctor before taking BALVERSA 5mg with other medications, as it may interact with CYP3A4 inhibitors or inducers.

No, BALVERSA 5mg is typically prescribed after other treatments, such as platinum-based chemotherapy, have been tried.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.